Erratum: Fracture prevention in postmenopausal osteoporosis: A review of treatment options (Obstetrical and Gynecological Survey (2006) 61 (39–50) DOI: 10.1097/01.ogx.0000197807.08697.06);Fracture prevention in postmenopausal osteoporosis: A review of treatment options

Obstetrical and Gynecological Survey

Volumn 61, Issue 1, 2006, Pages 39-50

  McCarus, David C ^a,b  

^a Center for Advanced Vein Treatment and Women's Health Care   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; IBANDRONIC ACID; MEDROXYPROGESTERONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STOMACH SECRETION INHIBITOR; STRONTIUM RANELATE;

ABDOMINAL PAIN; AEROSOL; BONE DENSITY; BREAST CARCINOMA; CARDIOVASCULAR DISEASE; CLAVICLE FRACTURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGITIS; ESOPHAGUS DISEASE; ESOPHAGUS IRRITATION; FEMALE; FRACTURE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HIP FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HUMERUS FRACTURE; LEG CRAMP; LEG FRACTURE; MEDICAL DECISION MAKING; MEDLINE; META ANALYSIS; MONOTHERAPY; NAUSEA; OSTEOSARCOMA; PELVIS FRACTURE; PERIPHERAL EDEMA; POSTMENOPAUSE OSTEOPOROSIS; PROPHYLAXIS; REVASCULARIZATION; REVIEW; RHINITIS; RISK FACTOR; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH ULCER; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCEROGENESIS; UPPER GASTROINTESTINAL TRACT; VERTEBRA FRACTURE; VOMITING; WRIST FRACTURE;

EID: 30144445121     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0000000000000889     Document Type: Erratum

References (83)

1. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. Washington, DC: National Osteoporosis Foundation, 2002.
2. Walker N, Norton R, Vander Hoorn S, et al. Mortality after hip fracture: regional variations in New Zealand. N Z Med J 1999;112:269-271.
3. Koike Y, Imaizumi H, Takahashi E, et al. Determining factors of mortality in the elderly with hip fractures. Tohoku J Exp Med 1999;188:139-142.
4. Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-1005.
5. Koot VC, Peeters PH, de Jong JR, et al. Functional results after treatment of hip fracture: a multicentre, prospective study in 215 patients. Eur J Surg 2000;166:480-485.
6. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323.
7. Cuddihy MT, Gabriel SE, Crowson CS, et al. Osteoporosis intervention following distal forearm fractures: a missed opportunity? Arch Intern Med 2002;162:421-426.
8. Gallagher TC, Geling O, Comite F. Missed opportunities for prevention of osteoporotic fracture. Arch Intern Med 2002;162:450-456.
9. Gehlbach SH, Bigelow C, Heimisdottir M, et al. Recognition of vertebral fracture in a clinical setting. Osteoporos Int 2000;11:577-582.
10. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001;286:2815-2822.
11. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-1352.
12. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91.
13. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082.
14. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443.
15. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541.
16. Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249.
17. Fosamax (alendronate sodium). Full prescribing information. Whitehouse Station, NJ: Merck & Co Inc, 2004.
18. Actonel (risedronate sodium). Full prescribing information. Cincinnati: Procter & Gamble Pharmaceuticals, 2005.
19. Boniva (ibandronate sodium). Full prescribing information. Nutley, NJ: Roche, 2005.
20. Quandt SA, Thompson DE, Schneider DL, et al. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 2005;80:343-349.
21. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-4124.
22. Quandt S, Thompson D, Schneider D, et al. Alendronate reduces the risk of clinical vertebral fracture in osteopenic women: data from FIT. Paper presented at: 1st Joint Meeting of the International Bone and Mineral Society (IBMS) and the European Society for Calcified Tissue (ECTS) [Abstract]; Madrid, Spain; 2001.
23. Levis S, Quandt SA, Thompson D, et al. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial. J Am Geriatr Soc 2002;50:409-415.
24. Cummings SR. Prevention of hip fractures in older women: a population-based perspective. Osteoporos Int 1998;8:S8-12.
25. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9:461-468.
26. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000;85:3109-3115.
27. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199.
28. Schnitzer T, Bone H, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1-12.
29. Rizzoli R, Greenspan SL, Bone G 3rd, et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988-1996.
30. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-126.
31. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-468.
32. Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within 6 months. Curr Med Res Opin 2004;20:433-439.
33. Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129-135.
34. Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003;88:542-549.
35. Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004;52:1832-1839.
36. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-340.
37. Sato Y, Iwamoto J, Kanoko T, et al. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005;64:811-816.
38. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-111.
39. Watts NB, Lindsay R, Li Z, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003;14:437-441.
40. Felsenberg D, Miller P, Armbrecht G, et al. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 2005; e-pub.
41. Recker R, Stakkestad JA, Chesnut CH 3rd, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004;34:890-899.
42. Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005;21:391-401.
43. Reginster JY, Wilson KM, Dumont E, et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab 2005;90:5018-5024.
44. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the Fracture Intervention Trial. Arch Intern Med 2000;160:517-525.
45. Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 2002;77:262-270.
46. Liberman UI, Hirsch LJ. Esophagitis and alendronate. N Engl J Med 1996;335:1069-1070.
47. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-1021.
48. Colina RE, Smith M, Kikendall JW, et al. A new probable increasing cause of esophageal ulceration: alendronate. Am J Gastroenterol 1997;92:704-706.
49. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002;77:1031-1043.
50. Lanza F, Sahba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Am J Gastroenterol 2002;97:58-64.
51. Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000;119:631-638.
52. Thomson AB, Marshall JK, Hunt RH, et al. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 2002;29:1965-1974.
53. US Food and Drug Administration. FDA Talk Paper. FDA updates hormone therapy information for post menopausal women. Available at: http://www.fda.gov/bbs/topics/NEWS/ 2004/NEW01022.html. Accessed March 29, 2004.
54. Rossouw J, Anderson G, Prentice R, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
55. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-1738.
56. Anderson G, Limacher M, Committee WsHIS. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-1712.
57. Genant HK, Lucas J, Weiss S, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997;157:2609-2615.
58. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
59. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-2897.
60. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9-16.
61. Randell KM, Honkanen RJ, Kroger H, et al. Does hormone-replacement therapy prevent fractures in early postmenopausal women? J Bone Miner Res 2002;17:528-533.
62. Cauley JA, Black DM, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 2001;110:442-450.
63. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
64. Shumaker SA, Legault C, Thal L, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-2662.
65. Evista (raloxifene HCl). Full prescribing information. Indianapolis: Eli Lilly and Co, 2003.
66. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-645.
67. Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-1143.
68. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-3617.
69. Kanis JA, Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003;33:293-300.
70. Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522-532.
71. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002;287:847-857.
72. Mosca L, Barrett-Connor E, Wenger NK, et al. Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 2001;88:392-395.
73. National Cancer Institute. Digest page: Study of Tamoxifen and Raloxifene (STAR) trial. Available at: http://www.cancer.gov/clinicaltrials/digestpage/ STAR. Accessed March 29, 2004.
74. Miacalcin (calcitonin salmon). Full prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp, 2003.
75. Chesnut C III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med 2000;109:267-276.
76. Forteo (teriparatide). Full prescribing information. Indianapolis: Eli Lilly and Co, 2002.
77. US Food and Drug Administration. FDA Talk Paper. FDA approves Teriparatide to Treat Osteoporosis. Available at: http://www.fda.gov/bbs/topics/ ANSWERS/2002/ANS01176.html. Accessed March 22, 2004.
78. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
79. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-321.
80. Marie PJ. Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate. Osteoporos Int 2003;14(suppl 3):S9-12.
81. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-468.
82. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-2822.
83. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-578.